4-溴-3-甲基异恶唑 | 101084-19-9

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 中文名称: 4-溴-3-甲基异恶唑
• 英文名称: 4-bromo-3-methyl-isoxazole
• 英文别名: 4-Brom-3-methyl-isoxazol；4-Bromo-3-methylisoxazole；4-bromo-3-methyl-1,2-oxazole
• CAS: 101084-19-9
• 化学式: C₄H₄BrNO
• 分子量: 161.986
• InChiKey: NXUGSYBTPQHKQB-UHFFFAOYSA-N

物化性质

• 沸点：
  143-145℃
• 密度：
  1.654±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-溴-3-甲基异恶唑 、 4-溴苯甲酸乙酯 在 三甲基氯硅烷 、 硼酸三丁酯 、 magnesium 、 1,2-二溴乙烷 、 lithium chloride 、 1,1'-双(二苯基膦)二茂铁 、 caesium carbonate 、 palladium dichloride 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 13.0h， 以60%的产率得到ethyl 4-(3-methylisoxazol-4-yl)benzoate
  参考文献：
  名称：

  铃木-Miyaura交叉偶联反应的一锅法实用的二（杂）芳基镁和二烯基硼酸镁硼酸酯的制备

  摘要：

  毫克乙：一个原子经济一锅合成通过在B存在（OBU）直接镁插入3和LiCl允许宽范围的官能化的（杂）芳基和链烯基溴化物以转换成镁diorganoboronates 2，其经历Suzuki-Miyaura与各种芳基（假）卤化物的交叉偶联反应（参见方案）。的两个芳基2被转印并在良好的产品提供优异的产率。

  DOI：

  10.1002/anie.201103022
• 作为产物：
  描述：

  3-甲基异恶唑 在 溴 作用下， 生成 4-溴-3-甲基异恶唑
  参考文献：
  名称：

  Quilico; Justoni, Rendiconti - Istituto Lombardo Accademia di Scienze e Lettere, A: Scienze Matematiche, Fisiche, Chimiche e Geologiche, 1936, vol. 69, p. 587,598

  摘要：

  DOI：

文献信息

• [EN] INHIBITORS OF CYCLIN‑DEPENDENT KINASE 12 (CDK12)<br/>[FR] INHIBITEURS DE LA KINASE 12 DÉPENDANTE DE LA CYCLINE (CDK12)
  申请人：SYROS PHARMACEUTICALS INC

  公开号：WO2023091726A1

  公开（公告）日：2023-05-25

  The present invention provides chemical compounds that inhibit one or more families of kinases (e.g., serine/threonine kinases, including one or more of the families of CDK proteins, and in particular, CDK12). More specifically, the present invention provides CDK12 inhibitors, of formula (I), pharmaceutically acceptable salts and isotopically labeled derivatives thereof, pharmaceutical compositions containing the compounds/inhibitors, and methods of their synthesis and use in treating proliferative diseases (e.g., a bladder cancer, a breast cancer, Ewing's sarcoma, a gastric cancer, a gastrointestinal cancer, a hematologic cancer, a lung cancer (e.g., small cell lung cancer (SCLC)), an ovarian cancer (e.g., a high grade serous ovarian cancer), a pancreatic cancer (e.g., pancreatic ductal adenocarcinoma (PDAC)), a brain cancer (e.g., glioblastoma), or a prostate cancer), alone or in combination with a second therapeutic agent. The proliferative disease can be a cancer, benign neoplasm, or pathologic angiogenesis, and any of the therapeutic methods or uses described herein can include a step of diagnosing the patient's disease. In other embodiments of the invention, the compositions described herein (e.g., the compounds, pharmaceutical compositions, and kits containing them) are used for the treatment of myotonic dystrophy (type 1 or type 2).

  本发明提供了抑制一个或多个激酶家族（如丝氨酸/苏氨酸激酶，包括一个或多个CDK蛋白家族，特别是CDK12）的化合物。更具体地说，本发明提供了式 (I) 的 CDK12 抑制剂、其药学上可接受的盐和同位素标记的衍生物、含有该化合物/抑制剂的药物组合物，以及它们的合成方法和用于治疗增殖性疾病（如、膀胱癌、乳腺癌、尤文氏肉瘤、胃癌、胃肠道癌、血癌、肺癌（如小细胞肺癌 (SCLC)）、卵巢癌（如、胰腺癌（如胰腺导管腺癌 (PDAC)）、脑癌（如胶质母细胞瘤）或前列腺癌）。增殖性疾病可以是癌症、良性肿瘤或病理性血管生成，本文所述的任何治疗方法或用途都可以包括诊断患者疾病的步骤。在本发明的其他实施方案中，本文所述的组合物（如化合物、药物组合物和含有它们的试剂盒）用于治疗肌营养不良症（1 型或 2 型）。
• Novel Small Molecule Bradykinin B₂ Receptor Antagonists
  作者：Christoph Gibson、Karsten Schnatbaum、Jochen R. Pfeifer、Elsa Locardi、Matthias Paschke、Ulf Reimer、Uwe Richter、Dirk Scharn、Alexander Faussner、Thomas Tradler

  DOI：10.1021/jm9002445

  日期：2009.7.23

  Blockade of the bradykinin B, receptor provides therapeutic benefit in hereditary angioedema (HAE) and potentially in many other diseases. Herein, we describe the development of highly potent B, receptor antagonists with a molecular weight of approximately 500 g/mol. First, known quinoline-based B-2 receptor antagonists were stripped down to their shared core motif 53, which turned out to be the minimum pharmacophore. Targeted modifications of 53 resulted in the highly water-soluble lead compound 8a. Extensive exploration of its structure-activity relationship resulted in a series of highly potent B-2 receptor antagonists, featuring a hydrogen bond accepting functionality, which presumably interacts with the side chain of Asn-107 of the B-2 receptor, Optimization of the microsomal stability and cytochrome P450 inhibition eventually led to the discovery of the highly potent and orally available B-2 receptor antagonist 52e (JSM 10292), which showed the best overall properties.
• US20140256700A1
  申请人：——

  公开号：——

  公开（公告）日：——
• Practical One-Pot Preparation of Magnesium Di(hetero)aryl- and Magnesium Dialkenylboronates for Suzuki-Miyaura Cross-Coupling Reactions
  作者：Benjamin A. Haag、Christoph Sämann、Anukul Jana、Paul Knochel

  DOI：10.1002/anie.201103022

  日期：2011.8.1

  Mg for B: An atom‐economical one‐pot synthesis by direct magnesium insertion in the presence of B(OBu)3 and LiCl allows a broad range of functionalized (hetero)aryl and alkenyl bromides to be converted into magnesium diorganoboronates 2, which undergo Suzuki–Miyaura cross‐coupling reactions with various aryl (pseudo)halides (see scheme). Both aryl groups of 2 are transferred and furnish the products

  毫克乙：一个原子经济一锅合成通过在B存在（OBU）直接镁插入3和LiCl允许宽范围的官能化的（杂）芳基和链烯基溴化物以转换成镁diorganoboronates 2，其经历Suzuki-Miyaura与各种芳基（假）卤化物的交叉偶联反应（参见方案）。的两个芳基2被转印并在良好的产品提供优异的产率。
• Quilico; Justoni, Rendiconti - Istituto Lombardo Accademia di Scienze e Lettere, A: Scienze Matematiche, Fisiche, Chimiche e Geologiche, 1936, vol. 69, p. 587,598
  作者：Quilico、Justoni

  DOI：——

  日期：——